Pfizer Inc. (NYSE:PFE) will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.

Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share in the year-ago period. Pfizer projects to report quarterly revenue at $14.09 billion, compared to $14.88 billion a year earlier, according to data from Benzinga Pro.

Guardant Health (NASDAQ:GH), on April 24, announced a strategic collaboration with Pfizer to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform.

Pfizer shares gained 0.6% to close at $23.05 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

• UBS analyst Trung Huynh maintained a Neutral rating and cut the price target from $28 to $24 on April 8, 2025. This analyst has an accuracy rate of 66%.
• Goldman Sachs analyst Asad Haider downgraded the stock from Buy to Neutral and slashed the price target from $32 to $25 on April 8, 2025. This analyst has an accuracy rate of 63%.
• Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 75%.
• Citigroup analyst Andrew Baum maintained a Neutral rating and cut the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 70%.
• Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $30 to $31 on Oct. 30, 2024. This analyst has an accuracy rate of 66%.

Considering buying PFE stock? Here’s what analysts think:

Read This Next:

• Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter

Photo via Shutterstock